The DOI matches its Crossref record.
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
Open accessAbstract
BACKGROUND Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic arthritis (JIA). METHODS This double-blind, withdrawal phase 3 trial enrolled patients with polyarticular course JIA (extended oligoarthritis, rheumatoid factor-positive or rheumatoid factor-negative polyarthritis, or systemic JIA without active systemic features) aged 2 years to younger than 18 years, and was done at 64 centres of the Paediatric Rheumatology International Trials Organisation and Pediatric Rheumatology Collaborative Study Group networks in 14 countries. Patients with psoriatic arthritis or enthesitis-related arthritis were enrolled for exploratory endpoints. During part 1 of the study, patients received oral open-label tofacitinib (weight-based doses; 5 mg twice daily or lower) for 18 weeks. Patients achieving at least JIA/American College of Rheumatology 30 response were randomly assigned (1:1) using an Interactive Response Technology system to continue tofacitinib or switch to placebo in part 2 of the study for 26 weeks. The primary endpoint was JIA flare rate by week 44 in part 2 in patients with polyarticular course JIA; the intention-to-treat principle was applied. Safety was evaluated throughout part 1 and part 2 of the study in all patients who received one dose or more of study medication. This trial is registered with ClinicalTrials.gov, NCT02592434. FINDINGS Between June 10, 2016, and May 16, 2019, of 225 patients enrolled, 184 (82%) patients had polyarticular course JIA, 20 (9%) had psoriatic arthritis, and 21 (9%) had enthesitis-related arthritis. 147 (65%) of 225 patients received concomitant methotrexate. In part 2, 142 patients with polyarticular course JIA were assigned to tofacitinib (n=72) or placebo (n=70). Flare rate by week 44 was significantly lower with tofacitinib (21 [29%] of 72 patients) than with placebo (37 [53%] of 70 patients; hazard ratio 0·46, 95% CI 0·27-0·79; p=0·0031). In part 2 of the study, adverse events occurred in 68 (77%) of 88 patients receiving tofacitinib and 63 (74%) of 85 in the placebo group. Serious adverse events occurred in one (1%) and two (2%), respectively. In the entire tofacitinib exposure period, 107 (48%) of 225 patients had infections or infestations. There were no deaths during this study. INTERPRETATION The results of this pivotal trial show that tofacitinib is an effective treatment in patients with polyarticular course JIA. New oral therapies are particularly relevant for children and adolescents, who might prefer to avoid injections. FUNDING Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.-S., Zeng, J., Mei, J., & Wang, P.-Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1110765 · Cited by 339
Martini, A., Lovell, D. J., Albani, S., Brunner, H. I., Hyrich, K. L., Thompson, S. D., & Ruperto, N. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00332-8 · Cited by 289
Self-citationBaricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194
JAK inhibition decreases the autoimmune burden in Down syndrome
Rachubinski, A. L., Wallace, E., Gurnee, E., Enriquez-Estrada, B. A., Worek, K. R., Smith, K. P., Araya, P., Waugh, K. A., Granrath, R. E., Britton, E., et al. (2024) · eLife · doi:10.7554/elife.99323 · Cited by 32
Metadata
- Authors
- Ruperto, N., Brunner, H. I., Synoverska, O., Ting, T. V., Mendoza, C. A., Spindler, A., Vyzhga, Y., Marzan, K., Grebenkina, L., Tirosh, I., Imundo, L., Jerath, R., Kingsbury, D. J., Sozeri, B., Vora, S. S., Prahalad, S., Zholobova, E., Butbul Aviel, Y., Chasnyk, V., Lerman, M., Nanda, K., Schmeling, H., Tory, H., Uziel, Y., Viola, D. O., Posner, H. B., Kanik, K. S., Wouters, A., Chang, C., Zhang, R., Lazariciu, I., Hsu, M.-A., Suehiro, R. M., Martini, A., Lovell, D. J., Cuttica, R., Akikusa, J., Chaitow, J., Wouters, C., Oliveira, S., Neiva, C., Santiago, M., Silva, C., Terreri, M., Magalhaes, C., De Souza, V, Bandeira, M., Chédeville, G., Houghton, K., Vazquez-Del Mercado, M., Rizo Rodriguez, J., Kobusinska, K., Alexeeva, E., Calvo Penades, I., Boteanu, A., Kasapcopur, O., Poyrazoglu, M., Erguven, M., Ozen, S., Al-Abadi, E., Bohnsack, J., Carrasco, R., Dare, J., Gottlieb, B., Wahezi, D., Jung, L., Klein-Gitelman, M., Zhang, Y., Wagner-Weiner, L., Tarvin, S., Vehe, R., Chiraseveenuprapund, P., Rivas-Chacon, R., De La Pena, W., Sagcal-Gironella, A., & Weiss, J.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 398
- Issue
- 10315
- Pages
- 1984-1996
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3212215487
- Cited by
- 195
- References
- 0
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01255-1
- The paper
- Ruperto, N., Brunner, H. I., Synoverska, O., Ting, T. V., Mendoza, C. A., Spindler, A., Vyzhga, Y., Marzan, K., Grebenkina, L., Tirosh, I., Imundo, L., Jerath, R., Kingsbury, D. J., Sozeri, B., Vora, S. S., Prahalad, S., Zholobova, E., Butbul Aviel, Y., Chasnyk, V., . . . Weiss, J. (2021). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)01255-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.